{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:34:04Z","timestamp":1766511244808,"version":"3.48.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejphar.2025.178427","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:27:27Z","timestamp":1764894447000},"page":"178427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association of aggression and anti-seizure medications in pediatric patients: Disproportionality analysis using the FDA adverse event reporting system"],"prefix":"10.1016","volume":"1011","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6187-2467","authenticated-orcid":false,"given":"Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178427_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1177\/0004867414548902","article-title":"Benzodiazepine use and aggressive behaviour: a systematic review","volume":"48","author":"Albrecht","year":"2014","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.178427_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12954-021-00504-5","article-title":"Relationship between benzodiazepine prescription, aggressive behavior, and behavioral disinhibition: a retrospective study in a Swiss prison","volume":"18","author":"Baggio","year":"2021","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.ejphar.2025.178427_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178427_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178427_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0163-8343(87)90028-4","article-title":"Three case reports of behavioral disinhibition with clonazepam","volume":"9","author":"Binder","year":"1987","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178427_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2025.178427_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040475","article-title":"Levetiracetam mechanisms of action: from molecules to systems","volume":"15","author":"Contreras-Garcia","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178427_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","author":"Hansen","year":"2018","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.ejphar.2025.178427_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178427_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003499.pub3","article-title":"Antiepileptics for aggression and associated impulsivity","author":"Huband","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2025.178427_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110427","article-title":"Anti-seizure medication is a minor causative factor in behavioral problems of children with Tuberous sclerosis complex","volume":"168","author":"Hulshof","year":"2025","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejphar.2025.178427_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1024466819989","article-title":"Brief report: clonazepam behavioral side effects with an individual with mental retardation","volume":"33","author":"Kalachnik","year":"2003","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.ejphar.2025.178427_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1248\/bpb.b21-00954","article-title":"Association of aggression and antiepileptic drugs: analysis using the Japanese adverse drug event report (JADER) database","volume":"45","author":"Kawada","year":"2022","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2025.178427_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/epi.13340","article-title":"Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment","volume":"57","author":"Klitgaard","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2025.178427_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drugalcdep.2012.09.019","article-title":"The triggering effect of alcohol and illicit drugs on violent crime in a remand prison population: a case crossover study","volume":"129","author":"Lundholm","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejphar.2025.178427_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11370","article-title":"A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ejphar.2025.178427_bib17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/phcfm.v12i1.2162","article-title":"General side effects and challenges associated with anti-epilepsy medication: a review of related literature","volume":"12","author":"Mutanana","year":"2020","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"10.1016\/j.ejphar.2025.178427_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2025.178427_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ejphar.2025.178427_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5694\/mja17.00951","article-title":"The management of epilepsy in children and adults","volume":"208","author":"Perucca","year":"2018","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejphar.2025.178427_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2025.178427_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejphar.2025.178427_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2025.178427_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","article-title":"Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"9","author":"Strzelczyk","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178427_bib25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bcp.13844","article-title":"Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report","volume":"85","author":"Supasitthumrong","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178427_bib26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/00207454.2022.2032045","article-title":"Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis","volume":"133","author":"Wang","year":"2023","journal-title":"Int. J. Neurosci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925011811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925011811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:28:08Z","timestamp":1766510888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925011811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0014299925011811"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178427","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of aggression and anti-seizure medications in pediatric patients: Disproportionality analysis using the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178427"}}